Drug Trial Radar · NCT00417937
A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily
Last checked: Nov 20, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Jan 2007
Primary completion
Jun 2007
Study completion Jun 2007
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Jan 4, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy and tolerability of azelaic acid 15% gel applied once daily versus twice daily in the treatment of patients with papulopustular rosacea.
Conditions
- Papulopustular Rosacea
Interventions
azelaic acid 15% gelDrug
15% gel, topically applied once daily for six weeks
azelaic acid 15% gelDrug
15% gel, topically applied twice daily for six weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator's global assessment scored on a seven point scaleTime frame: Measurements made during the course of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Intendis GmbH
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.